Both are now rarely used, and the manufacturer has discontinued their US supply
87: 12391246 [DOI] [PubMed] [Google Scholar] 108.Hare KJ, Vilsboll T, Asmar M, et al
doi: 10.1186/s12933-022-01474-z Summary Keywords glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, cardiovascular diseases, major adverse cardiovascular events, diabetes mellitus Citation Ferhatbegovi L, Mri D and Maci-Dankovi A (2023) The benefits of GLP1 receptors in cardiovascular diseases
This group lawsuit would be a separate MDL from people alleging other injuries due to GLP-1 drugs
This idea of less frequent dosing being an absolute tradeoff for efficacywere not certain well see that, Bradner said